|Mr. Onno van de Stolpe||Co-Founder, MD, CEO & Exec. Director||N/A||N/A||1959|
|Mr. Bart Filius M.B.A., MBA||CFO & COO||N/A||N/A||1970|
|Dr. Piet Wigerinck||Chief Scientific Officer||N/A||N/A||1964|
|Ms. Elizabeth Goodwin||VP of Investor Relations||N/A||N/A||N/A|
|Dr. Andre Hoekema||Chief Bus. Officer||N/A||N/A||1957|
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. The company's clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, and ulcerative colitis; Phase II trials for small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. Its clinical stage programs also comprise GLPG1690I, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof of concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, the company engages in the development of GLPG1972, which is in the ROCCELLA Phase II trial in osteoarthritis patients; MOR106 that is in Phase I and II trials in atopic dermatitis patients; and GLPG3312, a Toledo molecule, which is in Phase I clinical development for various indications. Galapagos NV has collaboration agreement with Servier for GLPG1972; Les Laboratoires Servier for GLPG1972; MorphoSys AG and Novartis Pharma AG for MOR106; AbbVie for the discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis; and Evotec for fibrosis, as well as a drug discovery research collaboration agreement with HitGen to identify small molecule leads. The company was founded in 1999 and is headquartered in Mechelen, Belgium.
Galapagos NV’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 8; Compensation: 5.